PDP1: A Potential Drug Target and Biomarker (G54704)

Target Name: PDP1

NCBI ID: G54704

PDP1

PDP1: A Potential Drug Target and Biomarker

Purine nucleoside degradation pathway gene (PDP1) is a gene that has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. PDP1 is a key enzyme in the purine nucleoside degradation pathway, which is involved in the metabolism of nucleosides, including the DNA and RNA bases. The function of PDP1 is to catalyze the hydrolysis of the nucleoside guanosine monophosphate (GMP) to guanosine, which is then converted to uracil by the enzyme guanosine nucleotide convertase (GNC).

PDP1 has been shown to be involved in various cellular processes, including cell growth, differentiation, and response to stress. It has also been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

As a potential drug target, PDP1 has been the focus of research to identify small molecules that can inhibit its activity and disrupt its function in disease. Studies have shown that inhibiting PDP1 can lead to therapeutic effects in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising small molecules that have been identified as potential inhibitors of PDP1 is called NX142. NX142 is a small molecule that is derived from a natural compound called the alkaloid pipelines, which are found in various plants and animals. Studies have shown that NX142 is a potent inhibitor of PDP1, with a half-maximal inhibitory concentration (HIC) value of 11 nM.

Another small molecule that has been shown to be an inhibitor of PDP1 is called MK-8628. MK-8628 is a small molecule that is derived from a natural compound called the alkaloid melittin, which is found in various plants and animals. Studies have shown that MK-8628 is a potent inhibitor of PDP1, with a HIC value of 8 nM.

In addition to NX142 and MK-8628, researchers have also identified a number of other small molecules that are potential inhibitors of PDP1. These molecules include natural compounds found in various plants and animals, as well as synthetic compounds that have been developed for drug discovery.

While the potential inhibitors of PDP1 have been identified, much work remains to be done to determine their efficacy and safety in clinical trials. Further studies are needed to determine the optimal conditions for the use of these inhibitors, including the appropriate dosage, frequency, and duration of treatment.

In addition to its potential as a drug target, PDP1 also has potential as a biomarker. The uracil generated by PDP1 hydrolysis can be detected in various biological fluids, including urine, plasma, and cerebrospinal fluid. Studies have shown that uracil levels in these biological fluids can be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

While more research is needed to fully understand the potential of PDP1 as a drug target and biomarker, its identification and characterization have the potential to lead to new therapeutic approaches for a variety of diseases.

Protein Name: Pyruvate Dehydrogenase Phosphatase Catalytic Subunit 1

Functions: Catalyzes the dephosphorylation and concomitant reactivation of the alpha subunit of the E1 component of the pyruvate dehydrogenase complex

The "PDP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets